FIGURE 7.
Exogenous Bcl-2 expression attenuates HtrA3-induced cell death in response to etoposide and cisplatin. A, immunoblots showing expression of exogenous WT and inactive HtrA3 variants and exogenous Bcl-2 in HtrA3-deficient lung cancer cell line H157. PDZ-deleted variants were detected using an HtrA3 polyclonal antibody. β-Actin shows equal loading. B and C, analysis of apoptosis activity with exogenous overexpression of WT and protease inactive HtrA3 variants and Bcl-2 with etoposide (B) or cisplatin (C) treatment in lung cancer cell line H157. Apoptosis activity was assessed by annexin V labeling followed by flow microfluorimetry. The percentage of cells in early (bottom right quarters) and late (top right quarters) stages of apoptosis is given.